Xenon Pharmaceuticals Inc (XENE) Actualités

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Xenon Showcases New Long-Term Azetukalner Data from X-TOLE OLE Study in FOS at AES 2024

– OLE data shows sustained monthly reduction in seizure frequency, impressive seizure freedom rates, and...

Xenon to Showcase New Long-Term Azetukalner Data at AES 2024

Five posters to be presented including new long-term 36-month data from the ongoing X-TOLE OLE study of...

Xenon to Present at Upcoming Investor Conferences

VANCOUVER, British Columbia and BOSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Xenon Reports Q3 2024 Financial Results and Business Update

– Phase 3 epilepsy program advancing with X-TOLE2 topline FOS data anticipated in H2 2025 – Long-term...

Xenon to Report Q3 2024 Financial Results on November 12, 2024

VANCOUVER, British Columbia and BOSTON, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:...

Xenon to Present at BofA Securities 2024 CNS Therapeutics Virtual Conference

VANCOUVER, British Columbia and BOSTON, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc...

Xenon Showcases Azetukalner Data at 15th European Epilepsy Congress

Three presentations highlighting long-term data and improved quality of life outcomes in adults with focal...

Xenon Expands Leadership Team with Matthew D. Ronsheim, Ph.D. as Chief Operating Officer

VANCOUVER, British Columbia and BOSTON, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc...

Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report